(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

被引：727

作者：

Kim, D ^{[1
]}

Wang, LP ^{[1
]}

Beconi, M ^{[1
]}

Eiermann, GJ ^{[1
]}

Fisher, MH ^{[1
]}

He, HB ^{[1
]}

Hickey, GJ ^{[1
]}

Kowalchick, JE ^{[1
]}

Leiting, B ^{[1
]}

Lyons, K ^{[1
]}

Marsilio, F ^{[1
]}

McCann, ME ^{[1
]}

Patel, RA ^{[1
]}

Petrov, A ^{[1
]}

Scapin, G ^{[1
]}

Patel, SB ^{[1
]}

Roy, RS ^{[1
]}

Wu, JK ^{[1
]}

Wyvratt, MJ ^{[1
]}

Zhang, BB ^{[1
]}

Zhu, L ^{[1
]}

Thornberry, NA ^{[1
]}

Weber, AE ^{[1
]}

机构：

[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 01期

关键词：

D O I：

10.1021/jm0493156

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.

引用

收藏

页码：141 / 151

页数：11

相关论文

共 53 条

[1] Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 [J].

Abbott, CA ;

Yu, DMT ;

Woollatt, E ;

Sutherland, GR ;

McCaughan, GW ;

Gorrell, MD .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20) :6140-6150

[2] Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors [J].

Ashton, WT ;

Dong, H ;

Sisco, RM ;

Doss, GA ;

Leiting, B ;

Patel, RA ;

Wu, JK ;

Marsilio, F ;

Thornberry, NA ;

Weber, AE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) :859-863

[3] 4-cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV [J].

Ashworth, DM ;

Atrash, B ;

Baker, GR ;

Baxter, AJ ;

Jenkins, PD ;

Jones, DM ;

Szelke, M .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (22) :2745-2748

[4]

BRANNER KA, 2002, 28 NAT MED CHEM S AM

[5] Substituted piperazines as novel dipeptidyl peptidase IV inhibitors [J].

Brockunier, LL ;

He, JF ;

Colwell, LF ;

Habulihaz, B ;

He, HB ;

Leiting, B ;

Lyons, KA ;

Marsilio, F ;

Patel, RA ;

Teffera, Y ;

Wu, JK ;

Thornberry, NA ;

Ann, AE ;

Parmee, ER .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (18) :4763-4766

[6]

Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254

[7] Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors [J].

Caldwell, CG ;

Chen, P ;

He, JF ;

Parmee, ER ;

Leiting, B ;

Marsilio, F ;

Patel, RA ;

Wu, JK ;

Eiermann, GJ ;

Petrov, A ;

He, HB ;

Lyons, KA ;

Thornberry, NA ;

Weber, AE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (05) :1265-1268

[8] 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors [J].

Coppola, GM ;

Zhang, YL ;

Schuster, HF ;

Russell, ME ;

Hughes, TE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (14) :1555-1558

[9] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].

DEACON, CF ;

NAUCK, MA ;

TOFTNIELSEN, M ;

PRIDAL, L ;

WILLMS, B ;

HOLST, JJ .

DIABETES, 1995, 44 (09) :1126-1131

[10] Glucagon-like peptide-1: A basis for new approaches to the management of diabetes [J].

Deacon, CF ;

Holst, JJ ;

Carr, RD .

DRUGS OF TODAY, 1999, 35 (03) :159-170

← 1 2 3 4 5 6 →